Filing Flows › Companies › IGC Pharma › Cash flow
IGC Pharma cash flow, quarter by quarter
Latest: Q3 2026 · from the cash-flow statements filed with the SEC
Free cash flow−$1.4M in Q3 2026
Analysis
In Q3 2026, IGC Pharma generated −$1.4M of operating cash flow. That is $702K more than in Q3 2025 (−$2.1M).
Operating cash flow was −$1.4M against net income of −$2.0M. The largest differences: stock-based pay −$200K, accrued liabilities +$63K, depreciation & amortization +$58K.
Its cash conversion cycle was -326 days (receivables 17 + inventory 221 − payables 565): suppliers fund its working capital.
Free cash flow
Cash runway and the debt wall
IGC Pharma is burning cash: its operations consume cash, a free cash flow of −$5.7M a year at the current rate against $413K of cash and investments: a runway of about 1 month before any new financing.
Where the cash came from and went
From profit to cash
| Quarter | Receivable days | Inventory days | Payable days | Cash conversion cycle |
|---|---|---|---|---|
| Q3 2026 | 17 | 221 | 565 | -326 |
| Q2 2026 | 16 | 268 | 602 | -318 |
| Q1 2026 | 7 | 220 | 390 | -163 |
| Q4 2025 | 7 | 195 | 247 | -45 |
| Q3 2025 | 31 | 1004 | 780 | 254 |
| Q2 2025 | 17 | 708 | 475 | 250 |
| Q1 2025 | 11 | 714 | 439 | 286 |
| Q4 2024 | 17 | 885 | 482 | 420 |
Every quarter
| Quarter | Operating cash flow | Capital spending | Net borrowing (+) / repaid (−) | Shares issued | Cash drawn (+) / kept (−) | Free cash flow |
|---|---|---|---|---|---|---|
| Q3 2026 | −$1.4M | — | −$1K | $2.0M | −$46K | −$1.4M |
| Q2 2026 | −$1.4M | −$5K | −$1K | $1.0M | −$124K | −$1.4M |
| Q1 2026 | −$1.2M | −$1K | $622K | $87K | $693K | −$1.2M |
| Q4 2025 | −$1.2M | −$12K | −$1K | — | $205K | −$1.2M |
| Q3 2025 | −$2.1M | −$29K | −$1K | $3.1M | −$651K | −$2.1M |
| Q2 2025 | −$1.4M | −$8K | −$1K | $852K | −$49K | −$1.4M |
| Q1 2025 | −$730K | −$18K | — | $805K | $65K | −$748K |
| Q4 2024 | −$1.3M | −$27K | −$1K | $346K | $1.1M | −$1.3M |
IGC Pharma: income statement and cash flow
IGC Pharma, Q3 2026: revenue $328K (+72% year over year), operating margin -588.7%. The chart follows the revenue to costs, profit and cash.
IGC Pharma: every quarter, Q/Q and Y/Y → Open in the app
Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.